Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 545 mg (equivalent: flucloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: povidone; titanium dioxide; purified talc; brilliant blue fcf; iron oxide red; magnesium stearate; iron oxide yellow; gelatin; microcrystalline cellulose; sodium starch glycollate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 272.5 mg (equivalent: flucloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: povidone; brilliant blue fcf; magnesium stearate; sodium starch glycollate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; microcrystalline cellulose; gelatin - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 526 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; quinoline yellow; gelatin; magnesium stearate; patent blue v; dimeticone 350; microcrystalline cellulose; carmellose sodium - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bact

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefalexin monohydrate, quantity: 263 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; dimeticone 350; magnesium stearate; titanium dioxide; patent blue v; quinoline yellow; microcrystalline cellulose; carmellose sodium - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bact

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin potassium, quantity: 277.18 mg (equivalent: phenoxymethylpenicillin, qty 250 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; iron oxide red; sodium lauryl sulfate; purified water - treatment of mild to moderately severe infections due to penicillin senstivie staphylococci, pneumococci, gonococci and haemolytic stretococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recent streptococcal infections including the prevention of recurrence following rhematic fever and/or sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/pr congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or childbirth.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin potassium, quantity: 554.37 mg (equivalent: phenoxymethylpenicillin, qty 500 mg) - capsule, hard - excipient ingredients: magnesium stearate; gelatin; titanium dioxide; iron oxide red; sodium lauryl sulfate; purified water - treatment of mild to moderately severe infections due to penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic stretococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recent streptococcal infections including the prevention of recurrence following rhematic fever and/or sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/pr congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or childbirth.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phenoxymethylpenicillin, quantity: 500 mg - capsule, hard - excipient ingredients: erythrosine; titanium dioxide; sunset yellow fcf; brilliant blue fcf; magnesium stearate; gelatin; indigo carmine; quinoline yellow aluminium lake; allura red ac; iron oxide black; sd alcohol 3-a - penicilin v potassium is indicated in the treatment of mild to moderately severe infections due to penicillin v sensitive micro-organisms. therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteraemia, pericarditis, meningitis and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - phenoxymethylpenicillin, quantity: 250 mg - capsule, hard - excipient ingredients: brilliant blue fcf; magnesium stearate; titanium dioxide; erythrosine; sunset yellow fcf; carbon black; gelatin; indigo carmine; quinoline yellow aluminium lake; allura red ac; iron oxide black; sd alcohol 3-a - treatment of mild to moderately severe infections due to penicillin v sensitive micro-organisms. therapy should be guided by bacteriological studies ( including sensitivity tests) and by clinical response. note: severe pneumonia, empyema, bacteraemia, pericarditis, meningitis and arthritis should not be treated with penicillin v during the acute stage. indicated surgical procedures should be performed. the following infections will usually respond to adequate dosage of penicillin v: streptococcal infections( without bacteraemia). mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. note: streptococci in groups a,c,g,h,l and m are very sensitive to penicillin. other groups, including group d (enterococcus) are resistant. pneumococcal infections. mild to moderately severe infections of the respiratory tract. staphylococcal infections-penicillin v sensitive. mild infections of the skin and soft tissues. note: reports indicate an increasing number of strains of staphyloco

Ireland - English - HPRA (Health Products Regulatory Authority)

athlone laboratories ltd - flucloxacillin - capsule, hard - 250 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

athlone laboratories ltd - flucloxacillin - capsule, hard - 250 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin